Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency

Neuroscience Letters

Volumn 509, Issue 2, 2012, Pages 101-104

  Poirier, R ^a   Fernandez, A M ^b   Torres Aleman, I ^b   Metzger, F ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Amyloid plaques; Inflammation; Liver derived; Reactive gliosis

Indexed keywords

AMYLOID BETA PROTEIN; SOMATOMEDIN C; UREA;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE EXACERBATION; FEMALE; GLIOSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY;

AGE OF ONSET; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BRAIN; FEMALE; GLIOSIS; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; TIME FACTORS;

EID: 84856383943     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.048     Document Type: Article

References (18)

1. Adlerz L., Holback S., Multhaup G., Iverfeldt K. IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J. Biol. Chem. 2007, 282:10203-10209.
2. Araki W., Kume H., Oda A., Tamaoka A., Kametani F. IGF-1 promotes beta-amyloid production by a secretase-independent mechanism. Biochem. Biophys. Res. Commun. 2009, 380:111-114.
3. Boucher J., Macotela Y., Bezy O., Mori M.A., Kriauciunas K., Kahn C.R. A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci. Signal. 2010, 3:ra87.
4. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 2002, 8:1390-1397.
5. Carro E., Trejo J.L., Gerber A., Loetscher H., Torrado J., Metzger F., Torres-Aleman I. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging 2006, 27:1250-1257.
6. Cohen E., Paulsson J.F., Blinder P., Burstyn-Cohen T., Du D., Estepa G., Adame A., Pham H.M., Holzenberger M., Kelly J.W., Masliah E., Dillin A. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
7. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
8. Fernandez A.M., Fernandez S., Carrero P., Garcia-Garcia M., Torres-Aleman I. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J. Neurosci. 2007, 27:8745-8756.
9. Freude S., Hettich M.M., Schumann C., Stohr O., Koch L., Kohler C., Udelhoven M., Leeser U., Muller M., Kubota N., Kadowaki T., Krone W., Schroder H., Bruning J.C., Schubert M. Neuronal IGF-1 resistance reduces Aβ accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 2009, 23:3315-3324.
10. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
11. Jimenez S., Baglietto-Vargas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 2008, 28:11650-11661.
12. Lanz T.A., Salatto C.T., Semproni A.R., Marconi M., Brown T.M., Richter K.E., Schmidt K., Nelson F.R., Schachter J.B. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem. Pharmacol. 2008, 75:1093-1103.
13. Richards J.G., Higgins G.A., Ouagazzal A.M., Ozmen L., Kew J.N., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., Huber G., Bluethmann H., Jacobsen H., Kemp J.A. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 2003, 23:8989-9003.
14. Saenger S., Goeldner C., Frey J.R., Ozmen L., Ostrowitzki S., Spooren W., Ballard T.M., Prinssen E., Borroni E., Metzger F. PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm. IGF Res. 2011, 21:292-303.
15. Torres-Aleman I. Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opin. Ther. Targets 2007, 11:1535-1542.
16. Trejo J., Piriz J., Llorens-Martin M.V., Fernandez A.M., Bolos M., LeRoith D., Nunez A., Torres-Aleman I. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol. Psychiatry 2007, 12:1118-1128.
17. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7324-7329.
18. Yakar S., Liu J.L., Fernandez A.M., Wu Y., Schally A.V., Frystyk J., Chernausek S.D., Mejia W., Le Roith D. Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50:1110-1118.